Data for Second-Line or Later Ramucirumab Show Consistent Benefit in Advanced HCC

Treatment with ramucirumab in the second line after first-line lenvatinib monotherapy or the combination of atezolizumab and bevacizumab, or as third-line treatment following both regimens, elicited efficacy comparable with second-line ramucirumab following treatment with sorafenib in patients with advanced hepatocellular carcinoma.

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Japan ,Japanese ,Kazufumi Kobayashi ,Department Of Gastroenterology ,International Liver Cancer Association Conference ,School Of Medicine Chiba University ,Liver Cancer Association ,Regarding Child Pugh ,Graduate School ,Chiba University ,Liver Cancer ,Hcc ,Hepatocellular Carcinoma ,Treatment Delays ,Hcc Treatment Delays ,2022 International Liver Cancer Association Conference ,Bilca ,2022 Ilca ,Ramucirumab ,